Overview

NACOS - The Effect of N-acetylcystein for Depressive Symptoms in Patients Suffering From Bipolar Depression

Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
This trial investigate add-on treatment with 3 g NAC vs. placebo in 20 weeks in patients suffering from bipolar depression. The primary outcome is MADRS-score, and the secondary outcomes are other psychometric evaluations oxidative stress biomarkers in urine.
Phase:
Phase 2
Details
Lead Sponsor:
Region Syddanmark
Treatments:
Acetylcysteine
N-monoacetylcystine